Boston Scientific Corporation

Recent News About Boston Scientific Corporation View More

BOSTON SCIENTIFIC CORPORATION: VICI VENOUS STENT® System Demonstrates Positive Clinical Outcomes in Patients with Deep Venous Blockages

Today, Boston Scientific (NYSE: BSX) announced positive 12-month data demonstrating that patients who were treated with the VICI VENOUS STENT® System for iliac and femoral vein obstructions exhibited a high rate of patent, or open, target lesions.

BOSTON SCIENTIFIC CORPORATION: Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement

Boston Scientific Corporation (NYSE: BSX) and Edwards Lifesciences Corporation (NYSE: EW) today announced that the companies have reached an agreement to settle all outstanding patent disputes between the companies in all venues around the world.

BOSTON SCIENTIFIC CORPORATION: Boston Scientific Exercises Option to Acquire Millipede, Inc.

Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Millipede, Inc, a privately-held company in Santa Rosa, Calif., upon its recent successful completion of a first-in-human clinical study.

Boston Scientific Corporation Upcoming Events View More

No Events

Metro Business Network